What if NICE’s risk-sharing deals don’t work?
Drugmakers have been trying to persuade the U.K.’s cost-effectiveness watchdog to pay for their pricier meds by offering risk-sharing discounts. Those deals–through which a drugmaker foots the bill for part of the treatment, or accepts payment only if treatment works–are why some expensive
